title: Blinatumomab significantly improves overall survival.
authors.forename: Talha Khan
authors.initials: TK
authors.lastname: Burki
mesh_terms: D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000074322:Antineoplastic Agents, Immunological; C510808:blinatumomab